UK regulators have given their approval for a prostate cancer drug that can delay the progression of the disease for more than a year. The drug - Pluvicto - has been given the green light by the Medicines and Healthcare products Regulatory Agency, as reported in The Independent.
It has been proclaimed as a “major clinical advance” by cancer experts and Pluvito could now be rolled out in the NHS before the end of the year. Prostate cancer is the most common form of cancer in men with more than 50,000 diagnosed with it in the UK every year.
It is also responsible for 12,000 annual deaths in this country. A total of 78 per cent of men diagnosed with the disease go on to live for more than 10 years, but that figure has not improved over the past decade, mainly because it is generally detected at a relatively late stage.
